ArticleJournal of Crohn's & colitis2026
Orofacial granulomatosis associated with Crohn's disease: clinical phenotype and response to biologics and Janus kinase inhibitor therapy in a large multi-center cohort.
Article in Journal of Crohn's & colitis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsOrofacial granulomatosis (OFG) is strongly associated with Crohn's disease (CD). The CD phenotype associated with OFG is poorly defined, and there is little evidence regarding treatment. We aimed to characterize OFG-associated CD phenotypes and evaluate the response of OFG to advanced therapies in the largest cohort described to date.
methodsWe conducted a retrospective cohort study of patients with OFG and CD from two UK centers, derived from patient records compiled since 2008. Phenotypic characteristics were compared with a CD control cohort of 1609 individuals without OFG from the NIHR IBD-BioResource. Clinical response to biologic/Janus kinase inhibitor (JAKi) therapies was assessed.
resultsA total of 117 patients were included. Compared with controls, OFG was associated with earlier CD diagnosis (<17 years: 43% vs 22%, P < .001), increased ileocolonic disease (61% vs 41%, P < .001), perianal disease (46% vs 35%, P = .012), and upper gastrointestinal disease (21% vs 8%, P < .001). Clinical remission was achieved in 29 of 53 (55%) prescribed infliximab and 35 of 59 (59%) prescribed adalimumab, with frequent dose escalation. Remission was achieved with ustekinumab, risankizumab, and upadacitinib in 14 of 25 (56%), 6 of 12 (50%), and 3 of 5 (60%), respectively in biologic-experienced patients. Higher anti-TNF drug levels were associated with higher odds of achieving treatment response (adalimumab OR 1.14 per 1 µg/mL increase, P = .049; infliximab OR 1.27, P = .047).
conclusionsOFG is associated with a distinct CD phenotype characterized by frequent UGI and perianal involvement. Advanced therapies, including anti-TNF, anti-IL23, and JAKi therapies, are effective, with evidence supporting dose optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.